Amneal Pharmaceuticals to Invest $200 Million in India for 2 New Plants

By By Rediff Money Desk, New Delhi
Oct 08, 2024 18:19
Amneal Pharmaceuticals will invest up to $200 million in India over the next four to five years to build two new manufacturing facilities in Ahmedabad. The facilities will focus on peptide synthesis and sterile fill-finish manufacturing.
New Delhi, Oct 8 (PTI) US-based Amneal Pharmaceuticals on Tuesday said it will invest up to USD 200 million (nearly Rs 1,680 crore) in India over the next four to five years to build two new manufacturing facilities in Ahmedabad.

Of two greenfield facilities planned, one will be for peptide synthesis and one for advanced sterile fill-finish manufacturing, the company said in a statement.

"In this latest expansion in India, Amneal will make a total net investment of between USD 150 million and USD 200 million over the next four to five years to build two new greenfield facilities...," it said.

Commenting on the development, Amneal Pharmaceuticals Co-Founders and Co-Chief Executive Officers Chirag Patel and Chintu Patel said, "With these new facilities, we are proud to be at the forefront of developing and manufacturing innovative, branded medicines at scale in India, which will supply the local market and the rest of the world."

The company which started operations in India in 2008, currently has eight manufacturing sites, including five in Ahmedabad with additional sites in Dahej, Hyderabad and Vizag, and commercial offices in Mumbai. It has invested approximately USD 600 million in India over the past 10 years.

These facilities have a collective capacity of producing up to approximately 60 million units of injectables and 8.5 billion tablets annually, the company said.
Source: PTI
Read More On:
indiainvestmentmanufacturingpharmaceuticalsahmedabadgreenfieldamneal pharmaceuticalsfacilitiespeptide synthesissterile fill-finish
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Shirdi Saibaba Sansthan: Tax Exemption on...

The Bombay High Court has ruled that the Shri Saibaba Sansthan Trust is eligible for...

CCI Approves JM Financial's Stake Buy in Credit...

India's Competition Commission (CCI) has cleared JM Financial's acquisition of a 43%...

India Mobile Congress 2024: Over 900 Startups...

Over 900 startups are expected to participate in India Mobile Congress's Aspire...

IndiGo Fined Rs 2 Lakh by Bureau of Immigration

The Bureau of Immigration has imposed a Rs 2 lakh fine on IndiGo for visa-related...

Atal Pension Yojana Enrolment Crosses 7 Crore

The Atal Pension Yojana (APY) has crossed 7 crore enrolments, marking a significant...

BIF Opposes Jio's Demand for Satcom Spectrum...

Broadband India Forum (BIF) has opposed Reliance Jio's demand to revise the...

Samsung Tops Festive Smartphone Sales with 20%...

Samsung led smartphone sales during the first phase of the festive season with a 20%...

IRB Infra Toll Revenue Jumps 19% to Rs 502 Cr...

IRB Infrastructure's toll revenue surged 19% to Rs 502 crore in September, driven by...

British Indian Voters Shift Rightward on...

A new report reveals British Indian voters are drifting towards Conservative views on...

Ola Electric Receives CCPA Show Cause Notice...

Ola Electric has received a show cause notice from the CCPA for alleged violations of...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2024 Rediff.com